FibroGen, Inc. is a research-based pharmaceutical company headquartered in San Francisco, focused on discovering, developing, and commercializing novel therapeutic agents to address serious unmet medical needs. The company has a global approach, with a notable presence in China, and is dedicated to advancing therapies at the frontiers of cancer biology and other life-threatening diseases. FibroGen's pipeline includes groundbreaking products aimed at significantly improving patient outcomes.
FibroGen has achieved significant milestones in its mission to innovate within the pharmaceutical industry. The company has developed a robust clinical trial program and has introduced world-class innovations in China. By focusing on responsible development and commercialization of its therapies, FibroGen has made a substantial impact on the global healthcare landscape, contributing to the advancement of treatments for serious conditions.
